Please upgrade your browser.
Help researchers and meet others who are dealing with renal cancers in a multimedia, feature-rich, environment. Login with Facebook or your email and meet survivors and their families. Better than Facebook, because your participation will help those who want to cure kidney cancer.
Join us for a live Facebook chat every Tuesday at 8 a.m. and 8 p.m. Central. The Kidney Cancer Association has more than 45,000 friends on Facebook and anyone interested in the eradication of death and suffering from this disease is welcome to join.
14.7 months median progression free survival; 28% confirmed partial response rate & 72% disease control rate at week 16.
Navigating Treatment Decisions for Your Metastatic Renal Cell Carcinoma, by David Quinn, PhD, MBBS, FRACP
Searchable list of abstracts submitted for the 2012 ASCO Genitourinary Cancers Symposium, held this week in San Francisco.
Ulka Vaishampayan, MD writes: Biomarkers represent the future of renal cancer therapeutics. With six new targeted-therapy agents receiving U.S. Food and Drug Administration approvals, and many more maturing toward becoming established therapies, optimization of these treatments has become a dire need of the moment. Current prognostic information is predominantly reliant on patient and tumor characteristics and is derived from basic clinical history, physical examination, and laboratory tests.
The well-informed kidney cancer patient is the empowered patient, but is it wise to rely on the interpretation of medical information by other lay people? Perhaps not. In this podcast we discuss the importance of doing your own fact-finding.
This page is dedicated to bringing you the most current information about clinical trials for papillary kidney cancer. In a small number of cases, papillary renal cell carcinoma is hereditary. This disease accounts for a small percentage of all cases of kidney cancer.
2012 Genitourinary Cancers Symposium Daily News: By: Sima Porten, MD, MPH, and Maxwell V. Meng, MD The past decade has seen significant advances in the treatment of patients with renal cell carcinoma, with the widespread adoption of minimally invasive surgical techniques and the approval of several targeted systemic agents for metastatic disease.
By: Thomas Powles, MD The introduction of agents targeting angiogenesis and the mTOR pathway have substantially improved the outcome of metastatic renal cell carcinoma (mRCC). Cytoreductive nephrectomy remains the standard of care in the era of targeted therapy. This is based on data from two randomized trials comparing nephrectomy and immune therapy with immune therapy alone.
|Powered by NeonCRM|